Gland Pharma Ltd - 543245 - Statement Of Deviation Or Variation For The Quarter Ended September 30,2022
Statement of Deviation or Variation for the quarter ended September 30,202226-10-2022
26-10-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on Q2FY23 Financial Results26-10-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on Q2 FY23 (Quarter and Half Year ended September 30, 2022) Financial Results26-10-2022
Gland Pharma Ltd - 543245 - Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2022
The Board of Directors at its meeting held on October 26, 2022 has inter-alia approved the Unaudited financial results of the Company for the quarter and half year ended September 30, 2022.26-10-2022
Gland Pharma Ltd - 543245 - Board Meeting Outcome for Board Meeting Outcome For Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2022
The Board of Directors at its meeting held on October 26, 2022 has inter-alia approved the Unaudited financial results of the Company for the quarter and half year ended September 30, 2022.26-10-2022
Gland Pharma Ltd - 543245 - Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0101 Name of the Signatory :- Sampath Kumar PallerlamudiDesignation :- Company Secretary and Compliance Officer17-10-2022
Here's why Mehul Kothari recommends buying Gland Pharma, Indian Oil
According to the technical analyst from Anand Rathi, Gland Pharma can rally to Rs 2,350, while IOC can spurt to Rs 83.14-10-2022
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Conference Call - Q2FY2311-10-2022
Gland Pharma Ltd - 543245 - Board Meeting Intimation for Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2022
Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2022 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 202210-10-2022